Cue Biopharma, Inc. ( CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases April 7, 2026 10:00 AM EDT Lucinda Warren - Interim CEO, Interim President,Principal ...
Health and wellness influencers are hawking unapproved treatments on the gray market. The future of the F.D.A.—and the health ...
Everyday Health on MSN
Can taking a GLP-1 drug every other week help you keep the weight off?
Preliminary research suggests that people who’ve used GLP-1 drugs to reach a healthy weight can spread out their injections without regaining lost pounds.
The Arvinas fair value estimate has shifted from US$14.56 to US$14.88 per share, a small move that still matters if you are tracking valuation updates closely. Street research ties this change to ...
User discovers new code in the Steam Client that points to a new feature that may display estimated frame rate data for each ...
New findings from a Sony employee's LinkedIn page underline why the company may stop releasing its valuable first-party AAA ...
Think about the most recent interesting thing that you learned about the world. The odds are that fewer people know what you ...
Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate ...
For the past 7 years, pharmaceuticals that work as glucagon-like peptide 1 (GLP-1) receptor agonists have dominated the weight-loss and diabetes markets. These drugs, currently so ...
Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results